Found: 118
Select item for more details and to access through your institution.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. 8, p. 5143, doi. 10.1002/alz.13859
- By:
- Publication type:
- Article
Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease.
- Published in:
- Movement Disorders, 2008, v. 23, n. 13, p. 1830, doi. 10.1002/mds.22097
- By:
- Publication type:
- Article
Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.
- Published in:
- 2000
- By:
- Publication type:
- journal article
PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP).
- Published in:
- 1999
- By:
- Publication type:
- journal article
Validation of ELISA Methods for Quantification of Total Tau and Phosporylated-Tau<sub>181</sub> in Human Cerebrospinal Fluid with Measurement in Specimens from Two Alzheimer's Disease Studies.
- Published in:
- Journal of Alzheimer's Disease, 2011, v. 26, n. 3, p. 531, doi. 10.3233/JAD-2011-110296
- By:
- Publication type:
- Article
A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.
- Published in:
- Alzheimer's Research & Therapy, 2016, v. 8, p. 1, doi. 10.1186/s13195-016-0178-x
- By:
- Publication type:
- Article
An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.
- Published in:
- Alzheimer's Research & Therapy, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13195-015-0136-z
- By:
- Publication type:
- Article
A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease.
- Published in:
- Alzheimer's Research & Therapy, 2010, v. 2, n. 2, p. 1, doi. 10.1186/alzrt30
- By:
- Publication type:
- Article
New pathways in drug discovery for alzheimer’s disease.
- Published in:
- Current Neurology & Neuroscience Reports, 2006, v. 6, n. 5, p. 372, doi. 10.1007/s11910-996-0017-8
- By:
- Publication type:
- Article
Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).
- Published in:
- 2014
- By:
- Publication type:
- Letter
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
- Published in:
- Acta Neuropathologica, 2011, v. 121, n. 5, p. 597, doi. 10.1007/s00401-011-0808-0
- By:
- Publication type:
- Article
Decision making in clinical trials: Interim analyses, innovative design, and biomarkers.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, v. 9, n. 4, p. 1, doi. 10.1002/trc2.12421
- By:
- Publication type:
- Article
Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 328, doi. 10.1016/j.trci.2019.05.007
- By:
- Publication type:
- Article
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018, v. 4, n. 1, p. 652, doi. 10.1016/j.trci.2018.10.001
- By:
- Publication type:
- Article
Evidence that semaphorin 4D is upregulated in neurons in Huntington's and Alzheimer's diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.043971
- By:
- Publication type:
- Article
"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, n. 1, p. 153, doi. 10.1016/j.jalz.2018.11.002
- By:
- Publication type:
- Article
O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1055, doi. 10.1016/j.jalz.2018.06.2844
- By:
- Publication type:
- Article
O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P216, doi. 10.1016/j.jalz.2018.06.2338
- By:
- Publication type:
- Article
O1‐02‐02: THE ANTI‐AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P215, doi. 10.1016/j.jalz.2018.06.2337
- By:
- Publication type:
- Article
IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P177, doi. 10.1016/j.jalz.2018.06.2283
- By:
- Publication type:
- Article
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, n. 4, p. 535, doi. 10.1016/j.jalz.2018.02.018
- By:
- Publication type:
- Article
National Institute on Aging – Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, n. 2, p. 261, doi. 10.1016/j.jalz.2018.01.001
- By:
- Publication type:
- Article
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, n. 10, p. 1117, doi. 10.1016/j.jalz.2017.02.009
- By:
- Publication type:
- Article
PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P250, doi. 10.1016/j.jalz.2017.06.109
- By:
- Publication type:
- Article
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS): FINDINGS FROM THE EXPEDITION3 TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1521, doi. 10.1016/j.jalz.2017.07.649
- By:
- Publication type:
- Article
COMPARISON OF BASELINE ARIA-H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI-SITE GLOBAL CLINICAL TRIAL WITH COHORT OF 2137 AD SUBJECTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P419, doi. 10.1016/j.jalz.2017.06.410
- By:
- Publication type:
- Article
PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1452, doi. 10.1016/j.jalz.2017.07.506
- By:
- Publication type:
- Article
THE PATIENT VOICE: EXPLORING TREATMENT PREFERENCES IN PARTICIPANTS WITH MILD COGNITIVE CONCERNS TO INFORM REGULATORY DECISION MAKING.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1522, doi. 10.1016/j.jalz.2017.07.650
- By:
- Publication type:
- Article
COMPARISON OF BASELINE ARIA-H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI-SITE GLOBAL CLINICAL TRIAL WITH A COHORT OF 2,137 AD SUBJECTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P37, doi. 10.1016/j.jalz.2017.06.2314
- By:
- Publication type:
- Article
SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P254, doi. 10.1016/j.jalz.2017.06.116
- By:
- Publication type:
- Article
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1260, doi. 10.1016/j.jalz.2017.06.1881
- By:
- Publication type:
- Article
2017 NIA-AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER’S DISEASE CONTINUUM.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P890, doi. 10.1016/j.jalz.2017.07.294
- By:
- Publication type:
- Article
SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER’S DISEASE DEMENTIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P251, doi. 10.1016/j.jalz.2017.06.111
- By:
- Publication type:
- Article
EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P37, doi. 10.1016/j.jalz.2017.06.2315
- By:
- Publication type:
- Article
DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1317, doi. 10.1016/j.jalz.2017.06.2022
- By:
- Publication type:
- Article
EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P605, doi. 10.1016/j.jalz.2017.06.650
- By:
- Publication type:
- Article
Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, n. 9, p. 977, doi. 10.1016/j.jalz.2016.03.009
- By:
- Publication type:
- Article
EXPLORING THE UTILITY OF CSF NEUROGRANIN LEVELS IN AN ALZHEIMER’S DISEASE CLINICAL TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1062, doi. 10.1016/j.jalz.2016.06.2218
- By:
- Publication type:
- Article
EXPOSURE-ADJUSTED ANALYSIS OF TREATMENT-EMERGENT ADVERSE EVENTS FROM EXPEDITION AND EXPEDITION2 TRIALS OF SOLANEZUMAB FOR THE TREATMENT OF ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P610, doi. 10.1016/j.jalz.2016.06.1211
- By:
- Publication type:
- Article
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, n. 5, p. 623, doi. 10.1016/j.jalz.2016.02.007
- By:
- Publication type:
- Article
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, n. 2, p. 110, doi. 10.1016/j.jalz.2015.06.1893
- By:
- Publication type:
- Article
Safety of solanezumab in the expedition-ext study up to 2 years in a mild to moderate Alzheimer’s disease population.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P741, doi. 10.1016/j.jalz.2015.06.1658
- By:
- Publication type:
- Article
Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P262, doi. 10.1016/j.jalz.2015.07.338
- By:
- Publication type:
- Article
Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P218, doi. 10.1016/j.jalz.2015.06.050
- By:
- Publication type:
- Article
Prospective quality-control monitoring in the context of a clinical trial.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P386, doi. 10.1016/j.jalz.2015.06.317
- By:
- Publication type:
- Article
Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P29, doi. 10.1016/j.jalz.2015.06.050
- By:
- Publication type:
- Article
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. 840, doi. 10.1016/j.jalz.2015.04.001
- By:
- Publication type:
- Article
Delayed-start analyses of solanezumab phase 3 expedition studies in mild Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P852, doi. 10.1016/j.jalz.2014.05.1689
- By:
- Publication type:
- Article
Cognition Impairment Precedes and Predicts Functional Impairment in Mild Alzhiemer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P621, doi. 10.1016/j.jalz.2014.05.1070
- By:
- Publication type:
- Article
Cognitive impairment precedes and predicts functional impairment in mild alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2014, v. 10, p. P203, doi. 10.1016/j.jalz.2014.04.256
- By:
- Publication type:
- Article